Gene Therapy in Ophthalmology Market Revenue to Expand Significantly by 2034, States DelveInsight Report | REGENXBIO, GenSight Biologics, Neurophth Therapeutics

The Key Gene Therapy in Ophthalmology Companies in the market include - REGENXBIO, GenSight Biologics, Neurophth Therapeutics, and others.

DelveInsight's "Gene Therapy in Ophthalmology Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Gene Therapy in Ophthalmology, historical and forecasted epidemiology as well as the Gene Therapy in Ophthalmology market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Gene Therapy in Ophthalmology, offering comprehensive insights into the Gene Therapy in Ophthalmology revenue trends, prevalence, and treatment landscape. The report delves into key Gene Therapy in Ophthalmology statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Gene Therapy in Ophthalmology therapies. Additionally, we cover the landscape of Gene Therapy in Ophthalmology clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Gene Therapy in Ophthalmology treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Gene Therapy in Ophthalmology space.

To Know in detail about the Gene Therapy in Ophthalmology market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gene Therapy in Ophthalmology Market Forecast [https://www.delveinsight.com/sample-request/gene-therapy-in-ophthalmology-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Gene Therapy in Ophthalmology Market Report:

*
The Gene Therapy in Ophthalmology market size was valued ~USD 50 million in 2020 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
Estimates indicate that in 2020, the United States accounted for the largest gene therapy market in ophthalmology, valued at approximately USD 35 million, with significant growth expected by 2034.

*
Within the EU4 and the UK, Germany held the largest revenue share in 2020, estimated at approximately USD 6 million, and is projected to experience substantial growth by 2034.

*
4D Molecular Therapeutics expects to present an interim analysis of the Phase II dose expansion of the PRISM study for 4D-150 in wet AMD at the Angiogenesis, Exudation, and Degeneration 2024 Conference, along with an update on the US FDA's feedback regarding the Phase III pivotal trial plan in February 2024.

*
Key Gene Therapy in Ophthalmology Companies: REGENXBIO, GenSight Biologics, Neurophth Therapeutics, and others

*
Key Gene Therapy in Ophthalmology Therapies: RGX-314, GS010, NFS-01, and others

*
The Gene Therapy in Ophthalmology market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gene Therapy in Ophthalmology pipeline products will significantly revolutionize the Gene Therapy in Ophthalmology market dynamics.

*
Of all diagnosed prevalent cases for selected ophthalmology gene therapy indications, Diabetic Retinopathy accounted for the highest number, with around 9,200,000 cases across the 7MM in 2020.

*
In the US, Diabetic Retinopathy accounted for the highest number of diagnosed prevalent cases, totaling around 4,800,000, whereas Leber Hereditary Optic Neuropathy had the fewest cases in 2020.

*
Within the EU4 and the UK, Germany recorded the highest number of treated Retinitis Pigmentosa cases, estimated at around 24,000 in 2020.

*
In 2020, Japan had an estimated total of around 800,000 cases eligible for wet-AMD treatment.

Gene Therapy in Ophthalmology Overview

Gene therapy in ophthalmology is a medical approach that aims to treat or prevent eye diseases by correcting or replacing defective genes responsible for visual impairments. The eye is particularly suitable for gene therapy because it is easily accessible, immune-privileged, and small in size, allowing precise delivery of therapeutic genes.

This therapy typically uses viral vectors (like adeno-associated viruses) or non-viral methods to deliver functional copies of genes to retinal cells, corneal cells, or other ocular tissues. Gene therapy is being explored for rare inherited retinal diseases such as Leber congenital amaurosis, retinitis pigmentosa, and choroideremia, as well as acquired conditions like age-related macular degeneration.

Get a Free sample for the Gene Therapy in Ophthalmology Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/gene-therapy-in-ophthalmology-market [https://www.delveinsight.com/report-store/gene-therapy-in-ophthalmology-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Gene Therapy in Ophthalmology Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gene Therapy in Ophthalmology Epidemiology Segmentation:

The Gene Therapy in Ophthalmology market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Gene Therapy in Ophthalmology

*
Prevalent Cases of Gene Therapy in Ophthalmology by severity

*
Gender-specific Prevalence of Gene Therapy in Ophthalmology

*
Diagnosed Cases of Episodic and Chronic Gene Therapy in Ophthalmology

Download the report to understand which factors are driving Gene Therapy in Ophthalmology epidemiology trends @ Gene Therapy in Ophthalmology Epidemiology Forecast [https://www.delveinsight.com/sample-request/gene-therapy-in-ophthalmology-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Gene Therapy in Ophthalmology Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gene Therapy in Ophthalmology market or expected to get launched during the study period. The analysis covers Gene Therapy in Ophthalmology market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gene Therapy in Ophthalmology Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gene Therapy in Ophthalmology Therapies and Key Companies

*
RGX-314: REGENXBIO

*
GS010: GenSight Biologics

*
NFS-01: Neurophth Therapeutics

Discover more about therapies set to grab major Gene Therapy in Ophthalmology market share @ Gene Therapy in Ophthalmology Treatment Landscape [https://www.delveinsight.com/sample-request/gene-therapy-in-ophthalmology-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Gene Therapy in Ophthalmology Market Drivers

*
FDA approvals of gene therapies (e.g., voretigene neparvovec/Luxturna) validating clinical effectiveness

*
Advancements in viral and non-viral vector technologies enabling precise gene delivery to ocular tissues

*
Favorable ocular environment for therapy (immune-privileged, small and accessible target tissue)

*
Growing investment in R&D by biopharmaceutical companies for novel ophthalmic gene therapies

Gene Therapy in Ophthalmology Market Barriers

*
Rising prevalence of inherited retinal disorders such as Leber congenital amaurosis, retinitis pigmentosa, and choroideremia

*
High cost of gene therapy treatments limiting patient accessibility and adoption

*
Complex regulatory pathways for approval of novel gene therapy products

*
Potential safety concerns including immune reactions or long-term effects

*
Limited long-term clinical data on durability and efficacy of gene therapies

*
Challenges in manufacturing and scalability of viral vectors for ocular applications

Scope of the Gene Therapy in Ophthalmology Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Gene Therapy in Ophthalmology Companies: REGENXBIO, GenSight Biologics, Neurophth Therapeutics, and others

*
Key Gene Therapy in Ophthalmology Therapies: RGX-314, GS010, NFS-01, and others

*
Gene Therapy in Ophthalmology Therapeutic Assessment: Gene Therapy in Ophthalmology current marketed and Gene Therapy in Ophthalmology emerging therapies

*
Gene Therapy in Ophthalmology Market Dynamics: Gene Therapy in Ophthalmology market drivers and Gene Therapy in Ophthalmology market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Gene Therapy in Ophthalmology Unmet Needs, KOL's views, Analyst's views, Gene Therapy in Ophthalmology Market Access and Reimbursement

To know more about Gene Therapy in Ophthalmology companies working in the treatment market, visit @ Gene Therapy in Ophthalmology Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/gene-therapy-in-ophthalmology-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Gene Therapy in Ophthalmology Market Report Introduction

2. Executive Summary for Gene Therapy in Ophthalmology

3. SWOT analysis of Gene Therapy in Ophthalmology

4. Gene Therapy in Ophthalmology Patient Share (%) Overview at a Glance

5. Gene Therapy in Ophthalmology Market Overview at a Glance

6. Gene Therapy in Ophthalmology Disease Background and Overview

7. Gene Therapy in Ophthalmology Epidemiology and Patient Population

8. Country-Specific Patient Population of Gene Therapy in Ophthalmology

9. Gene Therapy in Ophthalmology Current Treatment and Medical Practices

10. Gene Therapy in Ophthalmology Unmet Needs

11. Gene Therapy in Ophthalmology Emerging Therapies

12. Gene Therapy in Ophthalmology Market Outlook

13. Country-Wise Gene Therapy in Ophthalmology Market Analysis (2020-2034)

14. Gene Therapy in Ophthalmology Market Access and Reimbursement of Therapies

15. Gene Therapy in Ophthalmology Market Drivers

16. Gene Therapy in Ophthalmology Market Barriers

17. Gene Therapy in Ophthalmology Appendix

18. Gene Therapy in Ophthalmology Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=gene-therapy-in-ophthalmology-market-revenue-to-expand-significantly-by-2034-states-delveinsight-report-regenxbio-gensight-biologics-neurophth-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.